Skip to main content
main-content

Rheumatology

Rheumatology

21-01-2019 | Rheumatology | News | Article

Trial results back TNF inhibitor dose-reduction strategy in ankylosing spondylitis patients

A dose-reduction strategy may be feasible for ankylosing spondylitis patients in sustained clinical remission with tumor necrosis factor inhibitor treatment, findings from the open-label REDES-TNF trial suggest.

Source:

Arthritis Res Ther 2019; 21: 11

17-01-2019 | Rheumatology | News | Article

Real-world data support tocilizumab use in GCA patients

Tocilizumab treatment results in a “rapid and maintained” clinical improvement among patients with giant cell arteritis in routine clinical practice, researchers report.

Source:

Semin Arthritis Rheum 2019; doi:10.1016/j.semarthrit.2019.01.003

17-01-2019 | Rheumatology | News | Article

Anakinra may be a ‘viable treatment option’ for gout

Findings from a randomized trial suggest that treatment with the interleukin-1 receptor antagonist anakinra is noninferior to usual care for the treatment of gout flares.

Source:

Rheumatology 2019; doi:10.1093/rheumatology/key402

16-01-2019 | Rheumatology | News | Article

Gene expression profiling points to methotrexate nonresponders

Rheumatoid arthritis patients who are unlikely to respond to methotrexate could be identified based on their gene expression profiles before and 4 weeks after initiating treatment, say researchers.

Source:

Arthritis Rheum 2019; doi:10.1002/art.40810

15-01-2019 | Rheumatology | News | Article

Randomized data back EULAR guidelines for mycophenolate mofetil use in AAV

Mycophenolate mofetil is noninferior to cyclophosphamide for inducing remission among patients with antineutrophil cytoplasmic antibody-associated vasculitis, randomized trial data show.

Source:

Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2018-214245

11-01-2019 | Rheumatology | News | Article

News in brief

Predictors of outcomes identified in JIA-associated uveitis

Demographic factors, measures of disease activity, and the type of treatment used are associated with 2-year outcomes among patients with juvenile idiopathic arthritis-associated uveitis, according to findings from the ICON-JIA study.

10-01-2019 | Rheumatology | News | Article

Biologic combination therapy for RA may increase risk for side effects

Findings from a systematic review and meta-analysis suggest that rheumatoid arthritis patients who receive combination therapy with two biologic DMARDs are more likely to experience adverse events than those given one biologic.

Source:

Semin Arthritis Rheum 2018; doi:10.1016/j.semarthrit.2018.12.003

10-01-2019 | Rheumatology | News | Article

Serious infection risk compared across different biologicals

Findings from two registry studies of patients with rheumatoid arthritis suggest that serious infection risk may differ by the type of biological agent used.

Source:

Arthritis Care Res 2018; doi:10.1002/acr.23824
Ann Rheum Dis 2019; doi:10.1136/annrheumdis-2018-214326

04-01-2019 | Rheumatology | News | Article

News in brief

Payment program linked to reduced joint replacement spending

Implementation of a bundled-payment program has led to a “modest reduction” in spending on knee and hip replacement operations in the USA, say researchers.

03-01-2019 | Rheumatology | News | Article

Support for methotrexate use in PsA patients

Findings from an observational study suggest that methotrexate treatment, with a dose-escalation strategy targeting remission, improves the joint and skin manifestations of psoriatic arthritis.

Source:

Rheumatology 2018; doi:10.1093/rheumatology/key369

02-01-2019 | Rheumatology | News | Article

Editor's pick

Add-on omalizumab shows potential for SLE

Preliminary results from a phase Ib trial suggest that add-on treatment with the anti-IgE antibody omalizumab may be a feasible option for patients with systemic lupus erythematosus.

Source:

Arthritis Rheumatol 2018; doi:10.1002/art.40828

21-12-2018 | Rheumatology | News | Article

Editor's pick

Long-term impact unclear for knee OA medications

Findings from a systematic review and network meta-analysis published in JAMA indicate that it is not clear whether pharmacologic treatments offer long-term benefits for patients with knee osteoarthritis.

Source:

JAMA 2018; 320: 2564–2579

20-12-2018 | Rheumatology | News | Article

Editor's pick

Calprotectin levels predict relapse risk in RA, PsA patients treated with TNF inhibitors

Levels of serum calprotectin are significantly associated with the risk of disease relapse among tumour necrosis factor inhibitor-treated patients with rheumatoid arthritis or psoriatic arthritis, researchers report.

Source:

Arthritis Res Ther 2018; 20: 275

19-12-2018 | Rheumatology | News | Article

Targeting IL-1 ‘may not be effective’ for erosive hand OA

Findings from a randomized trial indicate that treatment with the interleukin-1α and -1β inhibitor lutikizumab does not improve pain or imaging outcomes among patients with erosive hand osteoarthritis.

Source:

Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2018-213336

19-12-2018 | Rheumatology | News | Article

News in brief

Abatacept may improve PROs in PsA patients

Treatment with abatacept is associated with improvements in patient-reported outcomes among individuals with psoriatic arthritis, study findings suggest.

17-12-2018 | Rheumatology | News | Article

Lupus tied to increased cancer risk

Findings from a meta-analysis indicate that systemic lupus erythematosus is associated with an increased risk for 16 types of cancer.

14-12-2018 | Rheumatology | News | Article

Support for abatacept–methotrexate combination therapy in RA patients

Adding abatacept to methotrexate improves disease activity and reduces structural progression among ACPA-positive rheumatoid arthritis patients with early erosion, Japanese researchers report.

Source:

RMD Open 2018; 4: e000813

13-12-2018 | Rheumatology | News | Article

Mortality predictors identified in patients with giant cell arteritis

Patients with large vessel involvement when diagnosed with biopsy-confirmed giant cell arteritis have a substantially increased risk of death relative to patients with no large vessel involvement, Italian researchers report.

Source:

Rheumatology 2018; doi:10.1093/rheumatology/key325

12-12-2018 | Rheumatology | News | Article

Hepatotoxicity reassurance for febuxostat-treated patients with gout and fatty liver disease

Results of an observational study provide preliminary evidence suggesting that patients with gout and fatty liver disease who are treated with febuxostat do not have an elevated risk for hepatotoxicity.

Source:

J Rheumatol 2018; doi:10.3899/jrheum.180761

10-12-2018 | Rheumatology | News | Article

Editor's pick

ACR/NPF guidelines for the treatment of PsA published

The American College of Rheumatology and the National Psoriasis Foundation have issued evidence-based guidelines for the pharmacologic and nonpharmacologic treatment of active psoriatic arthritis.

Source:

Arthritis Rheumatol 2018; doi:10.1002/art.40726
Arthritis Care Res 2018; doi:10.1002/acr.23789
J Psoriasis Psoriatic Arthritis 2018; doi:10.1177/2475530318812244

image credits